Investing Port

P/S	31.5
P/BV	10.12
EV/EBITDA	-5.83
EBITDA	-0.0998
Цена ао	12.3

Все параметры ⇨

		Недооценка Название Значение Оценка P/S 31.5 1 P/BV 10.12 1 P/E 0 EV/EBITDA -5.83 10	Эффективность Название Значение Оценка ROA, % -31.53 1 ROE, % -96.96 1
	Дивиденды Название Значение Оценка Div yield, % 0 DSI 0 0	Долг Название Значение Оценка Долг/EBITDA 0	Импульс роста Название Значение Оценка Рост прибыли, % 0 0 Рост цены акции, % 0 0 Рост дивидендов, % 0 0

Institutions	Объем	Доля, %
Jacob Asset Management Of New York LLC	78000	0.14
CHI Advisors LLC	1014840	1.8
Windmill Hill Asset Management Limited	757891	1.35
Adams Chetwood Wealth Management LLC	240968	0.43
Principal Global Investors, LLC	997878	1.77
First Trust Portfolios L.P.	10174	0.02
venBio Partners LLC	1298191	2.31
Bayview Asset Management Co., Ltd.	98700	0.18
Motif Capital Management, Inc	950	0
Allianz Global Investors U.S. LLC	19154	0.03
BlackRock Fund Advisors	3982306	7.08
Global X Management Company LLC	95122	0.17
Moloney Securities Asset Management	342000	0.61
Integral Health Asset Management, LLC	300000	0.53
SEI Investments Management Corp	260225	0.46
State Street Global Advisors	520610	0.93
Sio Capital Management, LLC	355963	0.63
Allianz Global Investors	30196	0.05
SSGA Funds Management Inc	1826074	3.25
Lyxor International Asset Management S.A.S.	94780	0.17

ETF	Доля, %	Доходность за год, %	Дивиденды, %
Virtus LifeSci Biotech Clinical Trials ETF	0.87	51.04	0.79

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1\u002F2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R\u002FR multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.